TLDR:
- Rubedo Life Sciences, a biopharmaceutical company, raised $40M in Series A financing to develop therapies targeting senescent cells.
- The funding will be used to advance lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis.
Article Summary:
Rubedo Life Sciences, based in Sunnyvale, CA, closed a $40M Series A financing round led by Khosla Ventures and Ahren Innovation Capital. The company, led by CEO Marco Quarta and Chief Business Officer Ali Siam, is focused on developing innovative therapies targeting senescent cells that drive chronic age-related diseases. Rubedo’s ALEMBIC™ drug discovery platform has engineered small molecules to selectively target different types of senescent cells involved in various chronic disorders.
The company plans to use the funds to advance their lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, with plans for Phase 1 studies. Rubedo is also working on therapies targeting senescent cells in pulmonary diseases like idiopathic pulmonary fibrosis (IPF), with a program that received a substantial grant from CIRM last year.
With investors like Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, and Italian Angels for Growth (IAG), Rubedo Life Sciences is positioning itself to make significant advancements in the field of biopharmaceuticals.
